ReviewAdvances in therapy2021

Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.

Shun Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.